Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews · Neuromuscular

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 50%Low 2 · 50%Moderate 0 · 0%High 0 · 0%

Withdrawals due to adverse events · people with TTR‐FAP

It is very uncertain whether diflunisal changes number of dropouts due to adverse events compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes only
RR 2.06 [0.39, 10.87]
1 study · 130 participants
Very low

Withdrawals due to adverse events · people with TTR‐FAP

Patisiran may leads to lower number of dropouts due to adverse events compared with placebo (low certainty).

1 finding from 1 review

Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes only
RR 0.33 [0.13, 0.82]
1 study · 225 participants
Low

Withdrawals due to adverse events · people with TTR‐FAP

Inotersen may leads to higher number of dropouts due to adverse events compared with placebo (low certainty).

1 finding from 1 review

Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes only
RR 8.57 [1.16, 63.07]
1 study · 172 participants
Low

Withdrawals due to adverse events · people with early‐stage TTR‐FAP

It is very uncertain whether tafamidis changes number of dropouts due to adverse events compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes only
RR 1.29 [0.3, 5.54]
1 study · 128 participants
Very low